Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
18.30
-0.38 (-2.03%)
Mar 5, 2026, 5:31 PM CET
101.99%
Market Cap 379.89M
Revenue (ttm) 55.93M
Net Income (ttm) 23.65M
Shares Out 20.76M
EPS (ttm) 1.11
PE Ratio 16.46
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68,663
Average Volume 93,847
Open 18.54
Previous Close 18.68
Day's Range 18.16 - 19.12
52-Week Range 5.20 - 31.85
Beta 0.66
RSI 38.18
Earnings Date Mar 24, 2026

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 22
Stock Exchange SIX Swiss Exchange
Ticker Symbol NWRN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.